Bayer withdraws follicular lymphoma drug Aliqopa after further trial fails
Frankfurt: Bayer has said it would voluntarily withdraw the follicular lymphoma drug Aliqopa, also known as copanlisib, from the U.S. market after a trial designed to confirm its benefit did not show the desired effect on overall survival.
The decision follows discussions with the U.S. Food and Drug Administration, Bayer said in a statement.
Based on a Phase II study, Aliqopa was granted accelerated approval by the FDA in 2017 for adults with follicular lymphoma whose disease had returned after at least two prior systemic therapies, but the go-ahead was contingent on further trials.
In a follow-up study the FDA had required, the addition of Aliqopa to standard immunochemotherapy did not meet the target for progression-free survival when compared to the control group in patients on standard immunochemotherapy, Bayer added.
Read also: Bayer expands global life science incubator network
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd